In this ongoing feature, AgencyIQ looks at public data to determine what the FDA is likely to do in the month ahead, including key deadlines, meetings, events, planned regulations, comment periods and more. The goal: To allow regulatory professionals to better anticipate and prepare for upcoming events and catalysts.
What we expect to be talking about in March:
Mifepristone: We expect that much of FDA’s monthly allotment of political capital and attention in March will be spent focusing on the abortion and miscarriage management drug mifepristone.
Fill out the form to read the full article.